Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
2 ^; K; j2 I, l6 M( r7 X# I! E7 o4 GNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 6 `" L; R1 U& [
+ Author Affiliations C- g( N2 D7 u. Q
, F9 v8 P( Z& I- f$ \" Q! t
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
4 y# h9 t2 r- N. ~2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
. a& @- ]2 _8 P3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan + s6 @: X( f1 F
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan . r' G# f' T2 d
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + N: f1 Q# q" D8 M
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
7 E- c4 A6 F# Z- @" k3 e7Kinki University School of Medicine, Osaka 589-8511, Japan . n7 k* Y# ~$ R4 p- S
8Izumi Municipal Hospital, Osaka 594-0071, Japan
4 U1 N0 X9 v& L' Z- O9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
. U, G$ O2 u6 w" tCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ?: K# C A/ N6 q. k. m
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
( [/ X# t" h4 V% B1 m
! U: u5 A1 D2 p6 f2 g |